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Summary
Guanylate binding proteins (GBPs) are a family of
large interferon-inducible GTPases that are
transcriptionally upregulated upon infection with
intracellular pathogens. Murine GBPs (mGBPs)
including mGBP1 and 2 localize to and disrupt
pathogen-containing vacuoles (PVs) resulting in
the cell-autonomous clearing or innate immune
detection of PV-resident pathogens. Human GBPs
(hGBPs) are known to exert antiviral host defense
and activate the NLRP3 inflammasome, but it is
unclear whether hGBPs can directly recognize and
control intravacuolar pathogens. Here, we report
that endogenous or ectopically expressed hGBP1
fails to associate with PVs formed in human cells
by the bacterial pathogens Chlamydia trachomatis
or Salmonella typhimurium or the protozoan
pathogen Toxoplasma gondii. While we find that
hGBP1 expression has no discernible effect on
intracellular replication of C. trachomatis and S.
typhimurium, we observed enhanced early
Toxoplasma replication in CRISPR hGBP1-deleted
human epithelial cells. We thus identified a novel
role for hGBP1 in cell-autonomous immunity that is
independent of PV translocation, as observed forReceived 21 October, 2015; revised 15 January, 2016; accepted 9
February, 2016. *For correspondence. E-mail eva.frickel@crick.ac.
uk; Tel. +44 208 816 2400; Fax +44 20 8816 2730.
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medium, provided the original work is properly cited.mGBPs. This study highlights fundamental
differences between human and murine GBPs and
underlines the need to study the functions of GBPs
at cellular locations away from PVs.
Introduction
The cytokine Interferon gamma (IFNγ) is an important
mediator of host response against an array of intracellular
pathogens (MacMicking, 2012). Such infections include
the apicomplexan parasite Toxoplasma gondii, in which
case IFNγ drives effector mechanisms to eliminate the fast
replicating acute phase tachyzoite stage. The
intravacuolar bacteria Chlamydia trachomatis and Salmo-
nella typhimurium are likewise targeted by IFNγ-driven
host responses in the acute stages of infection, resulting in
C. trachomatis reticulate bodies forming an aberrant
non-dividing form, and in S. typhimurium clearance (Kazar
et al., 1971; Pie et al., 1997). In response to infection, IFNγ
upregulates a vast number of proteins, with a family of
large GTPases, the Guanylate Binding Proteins (GBPs),
being among the most highly induced (Cheng et al., 1983).
GBPs have been studied in vitro or in murine models and
are important in immune activation and restricting intra-
cellular pathogens, including viruses, bacteria and proto-
zoan parasites (MacMicking, 2012).
In mice, mGBPs accumulate around pathogen-
containing vacuoles (PV) of intracellular pathogens such
as Toxoplasma (Degrandi et al., 2007; Virreira Winter
et al., 2011; Haldar et al., 2013; Selleck et al., 2013), C.
trachomatis (Coers et al., 2008; Haldar et al., 2013),
Mycobacterium bovis BCG (Kim et al., 2011) and S.
typhimurium (Meunier et al., 2014). At PVs mGBPs act
cooperatively to assemble host defense responses that
include an oxidative burst, the delivery of antimicrobial
peptides and the induction of autophagy (Kim et al., 2011).
Additionally, mGBPs promote the disintegration of
Salmonella-containing vacuoles thereby exposing
bacteria to the cytosol where they can activate the
cytosolic LPS sensor caspase-11 (Meunier et al., 2014).
Rapid activation of caspase-11 in response to infections
with Legionella pneumophila or Chlamydia muridarum
requires additional lysis-independent function of mGBPsLtd
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et al., 2015). In addition to their association with PVs
mGBPs also co-localize with the cytosolic bacterial
pathogens Listeria monocytogenes and Francisella
novicida (Kim et al., 2011; Man et al., 2015; Meunier
et al., 2015). The association of mGBPs with F. novicida
prompts bacteriolysis and the activation of the cytosolic
DNA sensor AIM2 (Man et al., 2015; Meunier et al., 2015).
Human GBPs are much less well understood, and their
functional significance remains largely unknown. hGBP5
promotes NLRP3 inflammasome assembly and conse-
quently IL-1β production in response to LPS and nigericin
(Shenoy et al., 2012). hGBP1 can mediate the inhibition of
endothelial cell proliferation (Guenzi et al., 2001) and has
been shown to exhibit anti-viral properties. When hGBP1
expression is silenced using small hairpin RNAs, Dengue
virus burden increases (Pan et al., 2012). hGBP1 also
mediates an antiviral effect against vesicular stomatitis
v i rus and encepha lomyocard i t i s v i rus when
overexpressed in HeLa cells (Anderson et al., 1999).
While these studies indicate that human GBPs have
relevance during pathogenic infection, we do not under-
stand which microbes they target and how the endoge-
nous proteins act.
The structure and biochemical properties of GBPs have
been studied in detail, with the structure of hGBP1
revealing a globular GTPase domain connected to an
arm-like extension, and revealing the very fast GTP
hydrolysis rate of 95min1 (Prakash et al., 2000). Some
hGBPs also have the ability to perform two consecutive
hydrolysis steps from GTP to GMP (Schwemmle and
Staeheli, 1994). hGBP 1, 2 and 5 contain a ‘CaaX’
prenylation motif at their C-terminus, implying a capacity to
target membranes.
In agreement with their biophysical properties and
observations made for mGBPs, hGBPs have been
postulated to recognize PVs formed by type II Toxoplasma
vacuoles as well as C. trachomatis PVs, also known as
inclusions (Tietzel et al., 2009; Al-Zeer et al., 2013;
Ohshima et al., 2014). It has been reported that
interference with hGBP1 and 2 expression in IFNγ-
primed cells led to increased C. trachomatis inclusions
size, indicating better growth of the bacteria in absence of
these proteins (Tietzel et al., 2009). Many of these studies
have relied on heterologously expressed proteins or an
antibody recognizing several GBP family members. A
recent study on Toxoplasma postulates no effect on
parasite restriction by hGBPs (Ohshima et al., 2014). It
thus remains unclear which, if any, hGBPs target
Toxoplasma PVs, and whether endogenous hGBPs can
target and restrict C. trachomatis.
Here, we demonstrate that hGBP1, in contrast to its
closest murine orthologues mGBP1 and 2 fails to
recognize PV formed by C. trachomatis, S. typhimurium© 2016 The Authors Cellular Microbiology Published by John Wiley & Sonsor Toxoplasma in human epithelial cells. Our data indicate
that hGBP1 is not essential for the execution of cell-
autonomous control of the replication of these pathogens
in unprimed and IFNγ-primed human epithelial cells.
However, in a similar manner to mGBPs, hGBP1 is able
to restrict Toxoplasma early after host cell infection. This
restriction cannot be attributed to an invasion mechanism,
but rather hGBP1 is responsible for delaying the onset of
parasite replication. GBPs have only been reported to play
a role in cell-autonomous control of infections if they
accumulated around the pathogen-containing vacuole.
Here we show that this is not the case for hGBP1. We thus
define a novel role for hGBP1 with its capacity to restrict
Toxoplasma in early infection without targeting to the PV.
Results
hGBP1 does not localize to intracellular pathogen
vacuoles in epithelial cells
Several mGBPs recruit to PVs in an IFNγ-dependent
manner, disrupt PV integrity and facilitate pathogen
destruction. We explored whether hGBP1 was able to
target intracellular vacuoles formed by the bacterial
pathogens C. trachomatis and S. typhimurium or the
parasite Toxoplasma. Human GBP1 is the closest
orthologue of mGBP2 previously shown to associate with
vacuolar C. trachomatis, S. typhimurium and Toxoplasma
in murine fibroblasts, epithelial cells, macrophages and
spleen tissue (Degrandi et al., 2007; Tietzel et al., 2009;
Virreira Winter et al., 2011; Al-Zeer et al., 2013; Haldar
et al., 2013; Selleck et al., 2013; Meunier et al., 2014). To
this end, we produced a specific peptide antibody that
could distinguish hGBP1 from all other hGBPs by
immunoblot, and additionally a pan-hGBP antibody that
recognized hGBPs 1, 2, 3 and 5 (Fig. S1A). While we
could not overexpress hGBP4, this family member is least
identical to hGBP1 so we are confident the antibody will
not cross react. We show that A549 cells express GBPs
including hGBP1 at steady state level and further
upregulate the protein in response to IFNγ (Fig. S1B).
To further characterize this newly generated anti-
hGBP1 antibody, we employed CRISPR/Cas9 technology
to generate a lung epithelial A549-derived cell line
lacking hGBP1 expression. A region 5′ to the GTPase
domain of Gbp1 was targeted for disruption, and deletion
was confirmed by sequencing and immunoblot (Fig. S1C
and D). The cells were further analysed by the pan-hGBP
antibody, demonstrating that other hGBPs are still intact
with normal protein expression (Fig. S1D). Using anti-
hGBP1 for immunofluorescence staining we found that
both naïve and IFNγ-primed and ΔhGBP1 cells exhibited
low background immunofluorescence intensity. In con-
trast, parental A549 cells showed a robust increase in the
anti-hGBP1 immunofluorescence signal when primed withLtd, Cellular Microbiology, 18, 1056–1064
1058 A. C. Johnston et al.IFNγ (Fig. S1E), demonstrating that anti-hGBP1 specifi-
cally detects endogenous hGBP1 in situ.
Having confirmed the specificity of theanti-hGBP1antibody
we asked whether hGBP1 associated with PVs. To do so, we
infected IFNγ-primed A549 cells with three representative
vacuolar pathogens. Immunofluorescent microscopy showed
that hGBP1 does not recruit around the PVs formed by C.
trachomatis (Fig. 1A),S. typhimurium (Fig. 1B) orToxoplasma
(Fig. 1C). This lack of recruitment was observed at all time
points tested (data not shown) and not affected by the
absence of presence of IFNγ priming (Fig. S2A to C).
In order to associate with membranes hGBPs first
transition into an active GTP-bound state and following
hydrolysis hGBPs in the GDP-bound state form tetramers
that can attach to membranes (Syguda et al., 2012). We
therefore considered that the anti-hGBP1 antibody failed
to detect hGBP1 in the active, membrane-associated
state. To test for this, we ectopically expressed hGBP1
N-terminally fused to mCherry. We observed that mCherry-
hGBP1 heterologously expressed in mouse embryonic
fibroblast (MEFs) localized to Toxoplasma PVs (Fig S3A).
Staining with anti-hGBP1 overlapped with the mCherry-
hGBP1 signal showing that anti-hGBP1 can detect hGBP1
in its active, membrane-associated state and indicating thatFig. 1. hGBP1 does not localize to the intracellular pathogen vacuole.
A. Immunofluorescent confocal image of C. trachomatis vacuoles 20hpi in mC
B. Immunofluorescent confocal image of S. typhimurium vacuoles 4hpi in A54
C. Immunofluorescent confocal image of Toxoplasma vacuoles in A549 cells p
All scale bars 10 μm.
© 2016 The Authors Cellular Microbiology PublishGBP1 fails to associate with PVs in human A549 cells. We
stained IFNγ induced MEFs with anti-hGBP1 to ensure our
antibody did not overlap with mGBPs at the PV (Fig S3B).
Last, we expressed mCherry-hGBP1 in A549 cells and
failed to observe any association of mCherry-hGBP1
Toxoplasma PVs (data not shown), further corroborating
our finding that in striking contrast to mGBP1 and 2, hGBP1
is not recruited to intact vacuolarmembranes of intracellular
pathogens in infected human cells.
hGBP1 restricts Toxoplasma, but not the intravacuolar
bacterial pathogens C. trachomatis and S. typhimurium
As the subcellular location of hGBP1 was not consistent
with observations made with mGBPs and the roles they
play during intracellular pathogen infection, we were
interested to determine whether hGBP1 could still play a
role in controlling these particular infections. We assessed
the ability of the pathogens to replicate in the absence of
hGBP1 in comparison to their wild-type cells. For C.
trachomatis and S. typhimurium infections, inclusion
forming unit (IFU) or colony forming unit (CFU) assays
were employed, respectively, in the presence or absence
of IFNγ. Priming cells with IFNγ restricted the replication
and growth of both C. trachomatis and S. typhimuriumherry-hGBP1 expressing A549 cells primed with 200 U/ml IFNγ. N = 2.
9 cells primed with 50 U/ml IFNγ stained for endogenous hGBP1. N = 3.
rimedwith 10 U/ml IFNγ at the indicated time points post infection.N = 3.
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Fig. 2. hGBP1 restricts growth of Toxoplasma gondii but not C. trachomatis or S. typhimurium
A. C. trachomatis IFUassayscarriedout inA549cells primedor notwith 200U/ml IFNγ, 40hpi.N = 2.Error bars represent standard error of themean (STEM).
B.S. typhimuriumCFUassays carried out in A549 cells primed or notwith 50 U/ml IFNγ, 6 and 25hpi.N = 3. Significancewas analysed by 2wayANOVA.
C. Plaqueassaysshowingviability ofToxoplasma incubated for6 h inWT,ΔhGBP1,ΔhGBP1+ hGBP1orΔhGBP1+ cherryA549cellsprimedornotwith10U/
ml IFNγ before seeding onto HFF. Counts were taken 4 days after HFF infection.N=5, ComplementationN= 3. Significance was analysed by 2way ANOVA.
hGBP1 restricts Toxoplasma away from the vacuole 1059(Fig. 2A and B). However, the ability of bacteria to sustain
themselves via replication in the presence or absence of
immune pressure was the same regardless of the
presence of hGBP1 (Fig. 2A and B). We then determined
whether Toxoplasma replication was influenced by the
absence of hGBP1. We compared the capacity of the
parasite to replicate and form plaques in fibroblasts after
an initial infection in A549 cells primed or not with IFNγ.
Type I or type II Toxoplasma were incubated in A549 cells
for 6 h, a time period too short for replication to occur,
meaning potential differences in plaque number would be
a result of parasite killing or early restriction. Twice as
many type II Toxoplasma were able to survive when the
infection took place in ΔhGBP1 cells, while type I parasites
remained unaffected (Fig. 2C). Intriguingly, this was still
true in cells that were not primed with IFNγ. An
immunoblot confirmed the presence of hGBP1 even at
basal steady state level (Fig. S1B). In accordance, the
number of viable Toxoplasma parasites was largely
reduced to levels seen in parental A549 cells when
ΔhGBP1 A549 cells were complemented with hGBP1
(Fig. 2C). Thus hGBP1 does not restrict replication of the
bacterial pathogens C. trachomatis and S. typhimurium,
but does promote restriction of type II Toxoplasma.© 2016 The Authors Cellular Microbiology Published by John Wiley & SonshGBP1 mediates early replication of Toxoplasma infection
As we determined that Toxoplasma underwent early
restriction by hGBP1, our next move was to identify the
stage at which parasites were limited. We excluded
differential invasion as a reason for the enhanced recovery
of parasites from ΔhGBP1 cells. FACS analysis of A549
cells infected with fluorescent parasites showed that
regardless of genotype of the cell, type II parasites invaded
around 50% of A549 cells when an MOI of 4 was used
(Fig. 3A). Immunofluorescence microscopy was used to
ensure that individual cells of each genotype were infected
with low and equivalent numbers of parasites (Fig. 3B). We
used immunofluorescence microscopy to assess the early
replication status of Toxoplasma in A549 cells. At 24 h post
infection (hpi) it was evident that ΔhGBP1 cells contained
more vacuoles filled with 2 or more parasites than co-
isogenic wildtype cells did (Fig. 3C). By counting the
number of parasites per vacuole over an infection time
course, we quantified the replication efficiency of Toxo-
plasma (Fig. 3D). At 12hpi significantly more vacuoles
contained parasites that had replicated once in the
ΔhGBP1 cells as compared to the wild-type counterpart,
regardless of IFNγ priming. By 18hpi, numbers of vacuolesLtd, Cellular Microbiology, 18, 1056–1064
Fig. 3. hGBP1 mediates early replication of Toxoplasma gondii.
A. FACS analysis determined the number of A549 cells that had been invaded by Toxoplasma 1hpi. Cells had been primed or not with 10 U/ml IFNγ.
Representative of 3 independent experiments.
B. Immunofluorescence confocal images taken at 1hpi show the same numbers of parasites enter individual cells.
C. Immunofluorescence confocal images of A549 cells primed or not with 10 U/ml IFNγ.
D. Replicating parasites were determined by counting the number of parasites within vacuoles at specified times post infection. N = 2. Significance
was analysed using 2way ANOVA.
All scale bars 10 μm.
1060 A. C. Johnston et al.containing 2 or 4 parasites, indicating 1 or 2 replication
cycles, respectively, were significantly increased in the
IFNγ primed ΔhGBP1 (Fig. 3D). Finally, counts taken at
24 h show a significantly increased number of vacuoles that
hold parasites that have undertaken 3 or more replication
cycles in the IFNγ primed ΔhGBP1 A549 cells.
Our observations suggest that hGBP1 can delay the
onset of parasite replication. We concluded that type II
Toxoplasma is restricted early after invasion in A549 cells
by a yet unknown mechanism driven by hGBP1 without
the protein targeting to the vacuole.© 2016 The Authors Cellular Microbiology PublisDiscussion
We find that hGBP1 mediates an initial attenuation of type
II Toxoplasma early post-infection, without impacting
subsequent replication of Toxoplasma, C. trachomatis or
S. typhimurium in human epithelial cells. The observed
early Toxoplasma attenuation is not because of a defect in
parasite invasion in the presence versus absence of
hGBP1. Rather, we hypothesize that hGBP1 either
mediates early killing or slows down early replication of
the parasite, as at 12, 18 and 24hpi the ΔhGBP1 cellshed by John Wiley & Sons Ltd, Cellular Microbiology, 18, 1056–1064
hGBP1 restricts Toxoplasma away from the vacuole 1061contain significantly more parasites that have undergone
replication. To our knowledge this is the first report
demonstrating that an IFN-inducible GTPase can restrict
growth of an intracellular PV-resident pathogen indepen-
dently of any detectable association of the GTPase with
the PV itself.
Cell-autonomous restriction pathways for intracellular
pathogens driven by host resistance proteins often see the
protein localize to PVs. For example, ubiquitin-driven
autophagy and galectin-mediated control of Salmonella
relies on a pathogen-localization step of ubiquitin and
galectin (Perrin et al., 2004; Thurston et al., 2012).
Additionally in mouse, Immunity Related GTPases (IRGs)
and GBPs mediate cell-autonomous killing by directly
localizing and disrupting PVs (Martens et al., 2005; Ling
et al., 2006). We clearly define that endogenous hGBP1 is
not targeted to C. trachomatis, S. typhimurium or
Toxoplasma. We do, however, show that hGBP1
possesses the ability to recruit to Toxoplasma PVs when
heterologously expressed in mouse fibroblasts (Fig. S3A).
These results suggest that human cells lack a cellular
pathway for the delivery of GBPs to PVs that is present in
mouse cells. In support of this model, we recently
demonstrated that the translocation of mGBP1 and
mGBP2 to PVs in mouse cells requires GKS proteins, a
subset of IRG protein found in mouse but not in human
cells (Haldar et al., 2015). Therefore, it appears likely that
the deficiency of hGBP1 recruitment to PVs in human cells
is due in part to the absence of GKS encoding genes from
the human genome.
Conflicting reports attributed hGBPs to have a function
in intracellular C. trachomatis, but not Toxoplasma control
in non-hematopoietic cells (Tietzel et al., 2009; Ohshima
et al., 2014). Both reports find hGBPs localized to PVs
24hpi. Reduction of bacterial inclusions upon ectopic
expression of hGBP1 and 2 was observed in HeLa cells.
Curiously the demonstrated localization of hGBP1 is
observed for wild type, GTPase-deficient and helical-
domain-only protein. We, and others, have previously
shown that GTPase-activity deficient mouse GBP1 does
not recruit to PVs (Kim et al., 2011; Virreira Winter et al.,
2011). It is conceivable that detecting overexpressed
hGBP1 with antibody staining presents with different
results than detection of endogenous hGBP1. Equally,
overexpressed hGBP1 might exert a different effect than
endogenous hGBP1 and HeLa cells may present with a
different restriction pathway than other epithelial cells.
Ohshima et al. successfully knocked out the entire GBP
locus in haploid fibroblast-like human cancer cells, with
the resulting cells showing no defect in IFNγ-induced cell-
autonomous control of Toxoplasma at 24hpi. The early
restriction of the parasite by hGBP1 we observe may have
been missed or may not exist in fibroblasts. They also
demonstrate that a low percentage of Toxoplasma PVs© 2016 The Authors Cellular Microbiology Published by John Wiley & Sonswere decorated with hGBPs at 6hpi. The staining was
carried out using an antibody against hGBP1-5, so it is
conceivable that the protein present at that location
comprises another family member(s). In contrast to our
findings, hGBP1 has been shown to localize to the
bacterial inclusion in THP1 macrophages and restrict C.
trachomatis as demonstrated by shRNA knockdown
(Al-Zeer et al., 2013). It remains to be investigated if
human GBPs can localize to PVs of other pathogens in
macrophages. Combined with our results, this leads us to
speculate that hGBP1 may restrict select pathogens in a
cell type- and localization-dependent manner.
hGBPs are highly upregulated in all stages of infection
with intracellular pathogens and are often found in
transcriptional analysis of patient samples. Combined
with knowledge acquired from murine studies, it is almost
certain that hGBPs have an impact on the control of these
infections. We find that hGBP1 plays a role in mediating
early restriction of Toxoplasma soon after infection without
directly localizing to the pathogen. Previous definitions of
how this host restriction factor family is acting against
vacuolar intracellular pathogens were reliant on the
protein being present at the vacuole. Clearly, we have to
rethink this rather simplistic assessment as a proxy for
potential functions especially for the human GBPs. Early
restriction of pathogens directly after invasion is the first
step a cell takes to combat the invading foreign agent.
These early restriction mechanisms have to act in a rapid
and precise manner in order to start the cascade of
intracellular defense mechanisms. Because hGBP1 is
expressed at steady state level and we observe its
defense activity even in absense of interferon priming, it
most likely interacts with and directs specific cellular
machineries that do not require induction. Future work will
elucidate the mechanism by which hGBP1 can mediate
early restriction of Toxoplasma.
Experimental procedures
Cell culture
A549 lung epithelial cells were grown in DMEM with glutamine
(Life Technologies) supplemented with 10% FBS and cultured at
37 °C in 5% CO2. Where appropriate, cells were stimulated
overnight by addition of human IFNγ (R&D Systems) to growth
media. Human foreskin fibroblasts (HFF) were maintained in
DMEM with glutamine supplemented with 1% FBS and cultured at
37 °C in 5% CO2.
Bacteria culture and infection
C. trachomatis serovar L2 434/Bu containing a GFP expression
vector (Wang et al., 2011) was propagated in Vero cells.
Elementary Bodies (EBs) were purified by sequential density
gradients (Saka et al., 2011), and MOI was determined for purified
EBs through infection of confluent Vero cells. For infections,Ltd, Cellular Microbiology, 18, 1056–1064
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and then added to tissue culture dishes containing cells. Infection
was facilitated by spinning for 30min at 1560 ×g at 10 °C.
Finally, infection was allowed to continue to the desired time
point at 37 °C and 5% CO2. S. typhimurium WT strain 22023S
(received from David Holden) was cultured in Luria-Bertani (LB)
broth and grown overnight at 37 °C in a shaking incubator. To
allow invasive properties of S. typhimurium, a further culture was
produced in anaerobic conditions, gently shaking for 2 h before
infection. An optical density reader was used to measure the
absorbance at 600 nm wavelength (OD600). The multiplicity of
infection (MOI) was calculated using 1.0164/OD600 = μl contain-
ing 1 × 106 bacteria and the bacteria were spun at 1000 rpm for
5min to synchronously infect cells. At 1hpi, cells were washed
with PBS and new DMEM medium was added containing
100 μg/ml gentamycin and 10mM HEPES. At 2hpi cells were
washed twice and 10 μg/ml gentamycin was added into new
DMEM medium.
Parasite culture and infection
Toxoplasma expressing luciferase/eGFP or tdTomato (RH type I
or Prugniaud type II) were maintained in vitro by serial passage
on monolayers of HFF cells. For infection, Toxoplasma were
syringe lysed from HFF cultures and added to cell cultures at an
MOI 2 for type I parasites, and MOI 5 for type II parasites. The
cultures were centrifuged at 1000 rpm for 5min to synchronize
infection, before being maintained at 37 °C in 5% CO2. Where
appropriate, parasites were irradiated in HFF cells with
15 000rads.
Antibodies
A unique sequence for hGBP1 was selected (QDLQTKMRRRKAC)
and the peptide conjugated to keyhole limpet haemocynin was
ordered from BioMatik Corporation, Canada. Rabbits were inocu-
lated with these peptides, and final bleeds taken after 11weeks
(APS, Cambridge).
Fixed immunofluorescent microscopy
For Toxoplasma and S. typhimurium infections, A549 cells were
plated on coverslips (Thermo Fisher) and cultured and infected as
above. The cells were fixed in 3% paraformaldehyde (PFA) and
permeabilized in Perm Quench (see Supporting Information)
before incubating sequentially with primary and secondary
antibodies diluted in PGAS (see Supporting Information) for 1 h
at room temperature. Coverslips with cells were washed in PBS,
with the final wash containing 1 μg/ml Hoechst. Coverslips were
mounted on glass slideswithMowiol 4-88. Slides were viewed on a
Zeiss Axioplan II Epifluorescence microscope or on an SP5-
inverted Confocal microscope and analysed using LAS-AF software.
Imageswere further formatted using ImageJ software. ForChlamydial
microscopy, A549 and MEF cells ectopically overexpressing
mCherry-hGBP1 were infected, as above. At 20hpi, cells were fixed
with 4% PFA, before being stained with Hoechst in PBS+300mM
Glycine. After thorough washing in PBS, slides were mounted with© 2016 The Authors Cellular Microbiology PublisMowiol containing 0.01% p-phenylenediamine (PPD). Slides were
visualized using a Zeiss 510 Inverted Confocal Microscope, and
analysed using Zen Blue software.Pathogen viability assays
An IFU assay was used to assess C. trachomatis replication. WT
and hGBP1-deficient A549 cells were plated to confluence in 12-
well plates and stimulated for approximately 16 h with 200U/ml
human IFNγ. Cells were infected with C. trachomatis, as above, at
an MOI of 1. At 40hpi, bacteria were harvested by lysing cells in
water for 10min at 37 °C with frequent mixing, and 5X sucrose-
phosphate-glutamic acid buffer (SPG) was added to a final
concentration of 1X. Bacteria-containing lysates were then added
to cell culture medium (DMEM+10% FBS), and 10-fold serial
dilutions were performed. These dilutions were used to infect
confluent Vero cells in black-walled 96-well plates, as above. At
24hpi, infected Vero cells were fixed and permeabilized for 5min
on ice with ice-cold Methanol, and blocked with 2% BSA in PBS.
Wells were stained with a mouse monoclonal anti-Chlamydia LPS
antibody, followed by goat anti-mouse IgG AlexaFluor 488 and
Hoechst. For each well, 10 images were taken on a Zeiss
Obzerver.Z1 scope using a 20X objective, and the number of
Chlamydia inclusions/field was enumerated and averaged across
the 10 images. The number of infectious units/well of A549 cells
was calculated, taking into account the well area represented by
each field and accounting for dilution. For each condition,
infections were performed in triplicate (3 wells of A549 cells) for
a single experiment. S. typhimurium CFU assays were performed
by infecting cells for desired period of time before washing twice
with ice-cold PBS and lysing with 0.5% Sodium deoxycholate
(NaDOC) (Sigma-Aldrich) in PBS. Each sample was mechanically
scraped and pipetted up and down. The lysates were diluted
appropriately in LB and spread on a pre-warmed 10 cm2 agar
plate, incubated overnight at 37 °C followed by colony counting.
Parasite viability was assessed by indirect plaque assay. A549
cells were infected with 300 type I parasites or 600 type II
parasites in 24 well plates for the desired length of time before
scraping and syringe lysing the cell layer to release the
Toxoplasma. This suspension was then plated onto confluent
HFF in a 24 well plate in serial dilutions of 1:2. This infection was
allowed to persist at 37 °C at 5% CO2 for 4 days, after which
plaques were counted using a microscope.Parasite invasion assay using Flow cytometry
A549 cells were infected with irradiated type II Pru parasites for
1 h before washing twice in PBS. Cells were lifted with 2X Trypsin,
before quenching in DMEM. The cell pellet was washed twice in
PBA (see Supporting Information) before fixing with 4% PFA for
20min on ice. PBA was added to quench reaction before
suspension was centrifuged at 1500 rpm for 3min at 4 °C, after
which cell pellet was resuspended in PBA and analysed on a BD
LSR-II. Results were analysed using FlowJo software.hed by John Wiley & Sons Ltd, Cellular Microbiology, 18, 1056–1064
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The mCherry or mCherry-hGBP1 plasmids were transfected into
A549 ΔhGBP1 or SV40 T-antigen immortalized Mouse Embryonic
Fibroblasts using lipid transfection.
CRISPR/Cas9 mediated deletion of Gbp1
The guide RNA sequence hGBP1 guide1, 5′ cattacacagcctatggtgg
3′ to human Gbp1 was selected using the optimized CRISPR
design site crispr.mit.edu. Oligonucleotides were synthesized
(Sigma-Aldrich) and annealed and cloned into the CRISPR vector
p48139 containing a puromycin selection cassette (Ran et al.
2013. pSpCas9 (BB)-2A-Puro (pX459)was a gift fromFengZhang.
Addgene plasmid no 48139), using the BbsI restriction site,
according to the Addgene CRISPR Genome Engineering Toolbox
(Zhang Lab) www.addgene.org/crispr/zhang/. Transfection of
A549 cells with hGBP1 guide RNA-containing p48139 plasmid
was performed using FuGENE6 reagent (Promega) according to
themanufacturer’s instructions. Selection using 2 μg/ml puromycin
was commenced 30–36 h post transfection and continued for 48 h.
The puromycin was then removed and the cells allowed to recover
before selecting individual clones. To confirm disruption of hGBP1,
clones were cultured and either lysed with cell lysis buffer
containing 1% Triton X100 (Sigma) for SDS-PAGE and immuno-
blotting with hGBP1-specific antibody or lysed with DNAreleasy
(Anachem Ltd) for subsequent DNA sequence analysis.
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